Compare Stocks → What President Biden's new law means for investors (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:LBPH Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLBPHLongboard Pharmaceuticals$20.84+0.7%$19.97$3.60▼$28.15$810.26M1.251.09 million shs193,678 shsElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLBPHLongboard Pharmaceuticals0.00%+2.83%+18.64%-2.73%+123.92%[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (Ad)Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLBPHLongboard Pharmaceuticals2.0723 of 5 stars3.53.00.00.02.71.70.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLBPHLongboard Pharmaceuticals3.00Buy$43.67109.53% UpsideCurrent Analyst RatingsLatest LBPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2024LBPHLongboard PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.005/3/2024LBPHLongboard PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$60.005/3/2024LBPHLongboard PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$32.00 ➝ $34.005/1/2024LBPHLongboard PharmaceuticalsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$36.004/16/2024LBPHLongboard PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.004/10/2024LBPHLongboard PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$60.003/15/2024LBPHLongboard PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.003/13/2024LBPHLongboard PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$32.003/13/2024LBPHLongboard PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$60.00(Data available from 5/20/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLBPHLongboard PharmaceuticalsN/AN/AN/AN/A$1.67 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLBPHLongboard Pharmaceuticals-$54.42M-$2.24N/AN/AN/AN/A-49.87%-46.04%8/1/2024 (Estimated)Latest LBPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/2/2024Q1 2024LBPHLongboard Pharmaceuticals-$0.48-$0.42+$0.06-$0.42N/AN/A3/12/2024Q4 2023LBPHLongboard Pharmaceuticals-$0.60-$0.62-$0.02-$0.62N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLBPHLongboard PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLBPHLongboard PharmaceuticalsN/A31.4331.43OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLBPHLongboard Pharmaceuticals63.28%Insider OwnershipCompanyInsider OwnershipLBPHLongboard Pharmaceuticals4.64%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableLBPHLongboard Pharmaceuticals5038.88 million37.08 millionOptionableLBPH HeadlinesRecent News About These CompaniesMay 16, 2024 | marketbeat.comLongboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Sees Significant Decline in Short InterestMay 14, 2024 | morningstar.comLongboard Pharmaceuticals Inc LBPHMay 11, 2024 | americanbankingnews.comHC Wainwright Analysts Lower Earnings Estimates for Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH)May 10, 2024 | marketbeat.comLongboard Pharmaceuticals (NASDAQ:LBPH) Trading Down 7.3%May 10, 2024 | marketbeat.comQ2 2024 EPS Estimates for Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Cut by HC WainwrightMay 7, 2024 | marketbeat.comLongboard Pharmaceuticals (NASDAQ:LBPH) Trading 6.1% Higher May 7, 2024 | marketbeat.comLongboard Pharmaceuticals' (LBPH) "Buy" Rating Reiterated at HC WainwrightMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Longboard Pharmaceuticals Amidst Positive Clinical Progress and Market Potential for BexicaserinMay 6, 2024 | businesswire.comLongboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)May 4, 2024 | finance.yahoo.comLongboard Pharmaceuticals Inc. (LBPH) Q1 2024 Earnings: Financial and Strategic DevelopmentsMay 3, 2024 | marketbeat.comLongboard Pharmaceuticals (NASDAQ:LBPH) Shares Down 5.7% May 3, 2024 | msn.comLongboard Pharmaceuticals EPS of -$0.42 beats by $0.07May 3, 2024 | marketbeat.comCantor Fitzgerald Reiterates "Overweight" Rating for Longboard Pharmaceuticals (NASDAQ:LBPH)May 3, 2024 | marketbeat.comLongboard Pharmaceuticals (NASDAQ:LBPH) Price Target Increased to $34.00 by Analysts at WedbushMay 2, 2024 | markets.businessinsider.comBuy Rating Affirmed on Longboard Pharmaceuticals with Promising Bexicaserin Developments and Regulatory Milestones AheadMay 2, 2024 | investorplace.comLBPH Stock Earnings: Longboard Pharmaceuticals Beats EPS for Q1 2024May 2, 2024 | businesswire.comLongboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdatesMay 2, 2024 | msn.comBaird Initiates Coverage of Longboard Pharmaceuticals (LBPH) with Outperform RecommendationMay 1, 2024 | marketbeat.comLongboard Pharmaceuticals (NASDAQ:LBPH) Coverage Initiated by Analysts at Robert W. BairdApril 29, 2024 | marketbeat.comLongboard Pharmaceuticals (NASDAQ:LBPH) Trading 6.2% Higher April 27, 2024 | marketbeat.com480,828 Shares in Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Purchased by Jennison Associates LLCNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsLongboard PharmaceuticalsNASDAQ:LBPHLongboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
